Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies by Castillo, SD et al.










UCL Cancer Institute, University College London, London WC1E 6BT, UK 
2
UCL Institute of Child Health & Great Ormond Street Hospital for Children, London 
WC1N 1EH, UK 
 
*To whom correspondence should be addressed: S.D.C. (sandra.castillo@ucl.ac.uk)  
 
Running title: PI3K in vascular anomalies 
 
Keywords (3-10): Vascular anomaly, vascular tumour, vascular malformation, PI3K, 
AKT, mTOR, signal transduction, targeted therapy 
 
Word count (<4000): 3,906 words 
 
Abstract (<300 words) 
 
Vascular anomalies are broadly divided in vascular tumours and malformations. These 
lesions are composed of abnormal vascular elements of various types, and mainly affect 
infants, children and young adults. Vascular anomalies may be painful, be complicated by 
bleeding, infection or organ dysfunction, and can have secondary effects on other tissues. 
Current treatment strategies include surgical excision, pulsed laser, and sclerotherapy, which 
are invasive with risk of recurrence. There are growing pharmacologic options for these 
vascular anomalies, but to date no specific targeted therapies have been developed. 
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases involved in signal 
transduction and vesicular traffic which modulate important cellular processes such as 
proliferation, growth and migration. Recent findings indicate that the PI3K signalling 
pathway is important in the pathogenesis of vascular anomalies. This provides an opportunity 
for repurposing PI3K inhibitors, already used in clinical trials for cancer treatment, for such 
lesions. Here, we provide an update on the classification of vascular anomalies, with their 
major features, and discuss the role of the PI3K signalling pathway in the pathogenesis of 
vascular anomalies and their clinical implications and therapeutic opportunities. 
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Vascular anomaly classification  
 
Vascular anomalies represent a broad spectrum of lesions, some with overlapping clinical 
features. Many of these entities were historically associated with several labels, used by both 
clinicians and pathologists, which created confusion and difficulty in management and 
evaluation of published data, since particular ‘diagnoses’ had different meanings and 
implications for patients and healthcare professionals. In order to address these issues, and to 
provide a common framework for both clinicians and researchers in this field, the 
International Society for the Study of Vascular Anomalies (ISSVA) proposed a classification 
system, which has since been widely adopted and recently updated [1,2]. 
In summary, the generic term “vascular anomaly” (VA) encompasses all such lesions, 
which are broadly subgrouped into vascular tumours and vascular malformations. Each of 
these categories contains a further range of entities, which are defined based on a 
combination of specific clinical, imaging and histopathological features (Table 1). This 
overall schema has now been generally adopted by clinicians, pathologists and radiologists 
[3-5]. 
Data from tertiary referral centres with specialist VA clinics indicate that by far the 
commonest type of vascular tumour is infantile type capillary haemangioma (IH), with much 
smaller proportions of congenital haemangiomas (CH), Kaposiform haemangioendothelioma 
/ Tufted haemangioma (KHE/TA) and other rare entities. In contrast, the “vascular 
malformations” group consists of more similar numbers each of venous malformations (VM), 
arteriovenous malformations (AVM), lymphatic malformations (LM) and capillary or mixed-
type vascular malformations [6] (Figure 1). 
For some lesions, such as AVM, the clinical and imaging features are often characteristic, 
but for many other entities definitive diagnosis requires histological evaluation of tissue 
samples in conjunction with the clinical features [2]. In addition, such tissue samples may 
provide prognostic or therapeutic information based on immunohistochemical expression of 
specific markers which, in combination with other techniques such as molecular profiling, are 
increasingly likely to direct individualised care with development of specific small molecule 
therapies [7]. 
In order to develop rational scientific approaches to further understanding of such lesions, 
it is essential that both basic scientists and clinicians/pathologists understand and use 
appropriate terminologies, including, for example, when describing the findings of animal 
models of disease (see later section). To this end, we provide a brief overview of the main 
clinicopathological features of common VAs. More detailed clinical and histopathological 
details are referenced [3,8]. 
Correct classification and terminology by basic scientists and clinicians allows specific 
associations regarding possible genetic aetiologies and mechanisms to be determined, as 
subsequently illustrated in relation to PI3K. This may be in relation to development of 
specific entities in addition to subclassification of genetic types of morphologically similar 
lesions. For example, in the case of infantile type haemangioma, depending on the presence 
or absence of other malformations and the distribution of the lesions, specific syndromic 
disorders may be identified (for example PHACE and LUMBAR) [9]. Whilst genetic 
understanding of VAs is increasing, with additional associations described [10-12], at present 
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the classification system remains based primarily on clinical, radiological and histological 
features, but it is likely that further refinement will occur with additional distinction of cases 




Infantile type capillary haemangioma (IH) 
This common lesion presents in infancy/early childhood, most often as a cutaneous mass 
lesion. It is histologically formed of numerous thin-walled vascular channels lined by bland 
endothelial cells with no atypia, which characteristically express GLUT-1 on immunostaining 
[13]. The precise appearance varies with the age of the lesion, with variably cellular, vascular 
and fibrous regions. The endothelial cell phenotype is thus similar to placental endothelium, 
raising several hypotheses regarding pathogenesis, in relation to endothelial/mesenchymal 
stem cells and vasculogenesis / angiogenesis [14-16]. In most cases there is spontaneous 




Congenital haemangioma (CH) often appears histologically similar to IH on needle 
biopsy, being composed of thin walled vascular spaces and bland endothelial cells (in 
resection specimens, congenital haemangiomata, especially RICH, may demonstrate stromal 
fibrosis and sclerosis [north ref]). However, such CH do not express GLUT-1 [18]. Their 
further classification is largely based on the clinical history, as non-involuting (NICH) or 
rapidly involuting (RICH), which may show histological differences at later stages [13,19-
21].  
 
Kaposiform haemangioendothelioma (KHE) and tufted angioma (TA) 
These entities are grouped together here since they demonstrate distinct, but similar, 
histological and immunohistochemical features. In both cases lesions are composed of 
lobules of endothelial cells with slit-like vascular spaces. KHE usually exhibit a diffuse or 
nested histological appearance whereas TA demonstrate typical ‘cannonball’ distribution of 
nodules throughout the dermis. In KHE the tumours appear solid at low power, whereas TA 
demonstrate characteristic foci of cellular nodules protruding into larger vascular spaces.Both 
lesions demonstrate co-expression of vascular endothelial markers, such as CD34, with 
lymphatic endothelial markers such as D2-40 (podoplanin). In KHE, D2-40 expression is 
diffuse whereas in TA it is usually around the periphery of the nodules. This ‘dual phenotype’ 
appears to be associated with particular development of Kassabach-Merritt syndrome, due to 




Vascular malformations usually also present in infancy or childhood but, in contrast to 
tumours, they progress but usually grow slowly with the patient, causing symptoms 
depending on site, size and subtype [1]. They are poorly circumscribed and often diffusely 
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infiltrating, with greater predilection to affect deep tissues / viscera. Vascular malformations 
are composed of collections of abnormal vessels, with simple lesions having a predominant 
vessel type, including arteries, veins, lymphatics and capillaries. Most lesions demonstrate 
background fibrofatty tissue, which may be infiltrated ‘normal’ tissue or part of the lesion in 
cases where there is evidence of a hamartomatous process. For example, the vascular (usually 
lymphatic) malformations associated with known overgrowth syndromes, such as Proteus, 
may be histologically indistinguishable from non-syndromic cases cases [26]. Vascular 
malformations are further classified according to the predominant vascular component, 
although it should be recognised that in histological sections most lesions may contain more 
than one component, in some cases with no one vessel type being prominent (mixed / 
combined type vascular malformations described according to the component elements).  
The general simple subtypes therefore include arteriovenous malformations (AVM), 
demonstrating abnormal connections between venous and arterial components, venous 
malformations (VM), composed of abnormal ‘dysplastic’ veins, often associated with 
thrombi and calcification, and lymphatic malformations (LM), composed of predominant 
abnormal thin-walled lymphatic channels. A capillary component may also be present 
[8,10,11]. Recently a distinct further clinical subtype has been proposed composed of VM 
with a prominent adipose component, congenital lipovascular anomaly (COLA) or 
fibroadipose vascular anomaly (FAVA) [27].  
The diagnosis of VAs can usually be made based on morphological findings in routine 
haematoxylin and eosin (H&E)-stained sections, but interpretation should always be in 
conjunction with clinical and radiological findings since sampling issues may hamper 
diagnosis in small biopsy specimens, particularly those with multiple elements. In some 
cases, distinction of specific components may be aided by immunohistochemical staining 
such as D2-40/LYVE1 for identification of lymphatic-type endothelium. [florez] It has also 
been suggested that expression of WT1 may be useful for distinction of vascular tumours 
from vascular malformations. ]Al Dhaybi]  
A range of VAs are also reported affecting other animals, such as mice, but veterinary 
pathological terminology generally may not equate to the above ISSVA schema and therefore 
lesions may require secondary classification for comparative purposes. Vascular lesions have 
often been termed “haemangioma” or “cavernous haemangioma” to represent a wide range of 
entities which in reality represent a spectrum of haemagiomas and VMs. Nevertheless, such 
lesions can be classified according to a description of the major components present, and 
therefore mapped to the ISSVA schema.  
 
Role of PI3K in vascular anomalies 
 
PI3Ks are a family of lipid kinases involved in signal transduction and vesicular traffic. 
There are eight catalytic isoforms of PI3Ks divided in three classes, based on protein 
structure and lipid substrate preference [28].  
Of specific interest in the context of VAs are the so-called class IA PI3Ks. These are 
heterodimers consisting of catalytic subunits (p110α, p110β and p110δ, encoded by the 
PIK3CA, PIK3CB, and PIK3CD genes, respectively) in complex with a p85-type of 
regulatory subunit (of which there are five isoforms, encoded by the PIK3R1, PIK3R2 and 
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PIK3R3 genes). The p85 regulatory subunit keeps the heterodimeric p85/p110 complex in an 
inactive, cytosolic state. Class IA PI3Ks signal downstream tyrosine kinase- and G protein-
coupled (GPCRs) receptors in the plasma membrane. Class I PI3K signalling can also be 
activated (directly or indirectly) through small GTPases, including Ras. 
In endothelial cells, PI3K signalling can be triggered by many stimuli, including the 
tyrosine kinase receptors from the Vascular Endothelial Growth Factor Receptor (VEGF-R) 
family downstream of VEGFs, and the TIE receptors, binding to angiopoietins (ANG), 
regulating pivotal vascular processes such as cell proliferation and survival, morphogenesis, 
and maturation [29]. Binding of the p85 regulatory subunit to activated tyrosine kinase 
receptors and their substrates in the plasma membrane, brings the p85/p110 complex to the 
membrane, and relieves the inhibitory function of the p85 subunit, thus activating the 
catalytic class IA PI3Ks. Upon activation, class I PI3Ks phosphorylate the 
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) lipid to PI(3,4,5)P3 (PIP3), a second 
messenger that triggers signalling pathways that include, among other effectors, the Akt/PKB 
and mTOR protein kinases and FOXO transcription factors, which ultimately modulate 
important cellular processes such as proliferation, growth and migration.  
PIK3CA (OMIM171834) was reported to be frequently mutated in cancer over a decade 
ago [30]. Cancer-associated mutations in PIK3CB and PI3K3CD have now also been 
reported, but at a much reduced frequency compared to PIK3CA [31]. These mutations most 
often occur in ‘hot-spots’, leading to constitutive activation of the catalytic subunit. 
Activation of the heterodimeric p85/p110 complex can also be achieved by mutations in the 
regulatory p85 subunits, a common event in malignancies [32]. 
In 2012, several independent groups documented the presence of PIK3CA mutations, 
similar to those found in some cancers, in several congenital overgrowth syndromes with no 
associated malignancy [33-36]. Lower frequency mutations were also observed in other PI3K 
pathway components, such as PIK3R2, AKT3 and MTOR [33-36]. These diseases have 
recently been grouped under the umbrella term of PROS “PIK3CA-Related Overgrowth 
Spectrum” [9]. These clinical entities cover segmental overgrowths composed by 
mesodermal tissues including adipose tissue, fibroblasts, muscle, and bone. Interestingly, a 
common feature of PROS diseases is the presence of vascular anomalies, suggesting a 
potentially important role of PIK3CA and other PI3K components in the pathogenesis of 
these lesions.  
In contrast to malignancies, where these mutations are almost exclusively present in 
epithelial cells, PI3K pathway mutations in PROS are almost exclusively found in cells from 
mesodermal origin. The aetiology of PROS syndromes are consistent with an early, post-
zygotic mutation that occurs early in embryonic development resulting in a mosaic presence 
of the PIK3CA mutation in the affected tissues.  
In an attempt to model PROS pathologies, expression of Pik3ca
H1047R
, the most common 
PIK3CA hot-spot activating mutation found in cancer and in PROS, was induced in a mosaic 
pattern in the embryonic mesoderm of mice [37]. While no apparent overgrowth was 
observed, they displayed venous malformations (VMs), the most common type of vascular 
malformation in humans. Additional studies from several groups have reported that one in 
four human VMs carries somatic hot-spot PIK3CA mutations, with low level mutation in 
other PI3K pathway components, such as AKT2, AKT3 and IRS2 [37-39]. Taken together, 
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these observations strongly indicate a causative role of PIK3CA mutation in this type of 
vascular anomaly. Accordingly, PI3K pathway inactivation either by inhibition of p110α (by 
small molecule inhibitors selective for this PI3K isoform) or mTOR (by rapamycin) leads to 
regression of PIK3CA-mutant VMs in mice [37,38], with rapamycin also documented to be 
effective in human patients with PIK3CA-mutant VMs [39,40].  
Previous studies have indicated an exquisite sensitivity of endothelial cells to PI3K 
pathway alteration. Indeed, both genetic inactivation and over-activation of p110α 
(ubiquitous or endothelial cell-specific) during mouse embryonic development lead to mid-
gestation lethality due to severe vascular defects [41,42]. This may explain why PIK3CA 
mutations in human disease are somatic, since germline mutations would expected to be 
incompatible with viable embryonic development.  
Mechanistically, p110α inactivation impairs endothelial cell migration whereas its 
overactivation leads to enhanced cell proliferation and possibly migration, defective mural 
cell coverage, and aberrant vascular network formation [37,38,41]. In addition, p110α 
activation has been shown to dampen the expression of arteriovenous specification markers 
(Eph-B4, Ephrin-B2, and COUP-TFII) as well as production of the cytokines PDGF-B and 
ANG2 [37,38], probably as a result of PI3K-mediated inhibition of the activity of the 
forkhead box O1 (FOXO1) transcription factor, known to stimulate the expression of both 
cytokines. PDGF-B is essential for the recruitment of mural cells [43], and autocrine 
secretion of ANG2 favours vessel destabilization [44]. 
Thus, the overall cellular and molecular effects triggered by PI3K pathway activation are 
consistent with the pathogenesis of vascular anomalies, which are formed by immature 
vessels, characterized by endothelial cell hyperplasia and abnormal mural cell coverage. 
 
Activation of PI3K pathway components in vascular anomalies  
 
As mentioned above, PI3K signalling is triggered by activation of tyrosine kinases, 
GPCRs and small GTPases in the plasma membrane. This generates a signalling cascade that 
engages a number of components and effectors depending on the cell type and tissue context. 
Taking into account the exquisite sensitivity of endothelial cells to PI3K alterations, 
alteration at any point in the pathway might also promote the formation of vascular 
anomalies. These pathway alterations are described in more detail below (Figure 2). 
Twenty years ago, germline activating mutations in the TEK gene, which encodes the 
endothelial cell TIE2 tyrosine kinase receptor, were identified as the genetic cause of the 
inherited vascular anomaly mucocutaneous VM (MCVM) [45]. Similar mutations were also 
demonstrated in about half of sporadic VMs [46]. Thus, somatic TEK and PIK3CA mutations 
account for over 75% cases of sporadic VMs. Interestingly, in sporadic VMs, mutations in 
TEK are mutually exclusive with PIK3CA mutations [37,38]. This is consistent with previous 
observations showing that wild-type and mutant TIE2 signal through PI3K [40,47-49]. Also, 
the wild-type and mutant forms of TIE2 are known to signal partially through the mitogen-
activated protein kinase (MAPK) signalling pathway in endothelial cells [40,48-50]. Of note, 
the MAPK signalling pathway has been also found to be over-activated in vascular anomalies 
by genetic mutation of its components or by indirect alterations [12], but this will not be 
described further in the present review.  
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PI3K and MAPK signalling pathways are also activated in cells derived from infantile 
hemangiomas, as a consequence of constitutive activation of the VEGFR2 tyrosine kinase 
receptor,  in some cases as a result of missense mutations in the KDR gene which encodes 
VEGFR2 [51]. Likewise, VEGF-A and VEGFRs are over-expressed in angiosarcoma, the 
most aggressive type of vascular tumours [52]. 
The phosphatase and tensin homologue deleted on chromosome 10 gene (PTEN) encodes 
the PTEN phosphatase that dephosphorylates PIP3 to PIP2, thus negatively regulating the 
activity of the PI3K pathway. Germline inactivating mutations in PTEN are the underlying 
cause of two disorders that predispose to cancer, namely Bannayan-Riley-Ruvalcaba and 
Cowden syndromes. Most of these patients show a spectrum of vascular anomalies with 
predominance of arteriovenous and venous malformations [53].  
The Ser/Thr protein kinase AKT, the best characterized PI3K effector, has been also 
related to the pathogenesis of vascular anomalies. Upon PI3K activation, AKT binds to PIP3 
in the plasma membrane allowing its phosphorylation by other kinases and its subsequent 
activation. Antibodies to these phosphorylated forms of AKT (pAkt) are often used as proxy 
markers for PI3K pathway activation. There are three AKT isoforms (AKT1, AKT2, and 
AKT3), encoded by distinct genes, with the AKT1 isoform predominantly expressed in 
endothelial cells [54]. Overexpression of an active form of AKT1 in the murine endothelial 
cell line MS1 is associated with vascular malformations when these cells are injected as 
mouse xenografts [55]. Genetic mouse models with endothelial cell-specific AKT1 over-
activation also leads to vascular anomalies with enlarged vessels with increased permeability 
due to deficient mural cell coverage [56]. Importantly, human vascular tumours including 
infantile hemangioma, Kaposiform haemangioendotheliomas, and angiosarcomas display 
increased levels of active AKT (pAKT) compared to adjacent normal blood vessels [57,58]. 
At present, it is not clear if this is due to mutations in AKT or other upstream PI3K pathway 
components in these diseases. Gain-of-function mutations in the AKT2 and AKT3 isoforms 
have also been also found in human VMs [38].  
Proteus syndrome, a complex disorder with overgrowth and malformations of multiple 
tissues [59], is caused by activating somatic AKT1 mutations that are mosaic in the affected 
tissues [60]. A major manifestation of this syndrome is the presence of vascular 
malformations, either capillary, venous or/and lymphatic [59], highlighting the role of 
aberrantly active AKT1 in the development of such vascular anomalies. 
Mammalian target of rapamycin (mTOR) is a Ser/Thr protein kinase (downstream of 
AKT) that coordinates important cellular processes including cell growth and survival. 
mTOR phosphorylates and activates the p70-S6 kinase (encoded by the RPS6KB1 gene) 
which phosphorylates the S6 ribosomal protein. The phospho-form of S6 (referred to as pS6) 
is often used as a cellular marker of mTOR activation. Endothelial cells from vascular 
tumours and malformations are often immuno-positive for pS6, therefore mTOR is expected 
to be active in these pathologies [61-63]. However, it is important to stress that the S6 protein 
can also be phosphorylated upon MAPK pathway activation at sites that are also 
phosphorylated by p70-S6K [64], thus it is difficult to distinguish whether these vascular 
anomalies show PI3K or MAPK pathway activation, or both. Currently, it is unclear whether 
mTOR activation in the vascular anomalies analysed in these studies is the result of genetic 
mutation in PI3K or MAPK pathway components upstream of mTOR,  
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mTOR is negatively regulated by the tuberous sclerosis complex (TSC), encoded by the 
TSC1 or TSC2 genes. Mice with endothelial cell-specific deletion of Tsc1, a negative 
regulator of mTOR, develop lymphangiosarcomas, a type of angiosarcomas with lymphatic 
differentiation [63]. This aberrant activation of mTOR also leads to autocrine VEGF 
production and signalling, which contributes to the development and maintenance of these 
tumours. The human tuberous sclerosis syndrome is a multi-system genetic syndrome caused 
by inactivating mutations in either TSC1 or TSC2 genes, leading to constitutive mTOR 
activation. Among other clinical manifestations, TSC patients show growths of vascular 
tissue such as facial angiofibromas and kidney angiomyolipomas [65]. Glomuvenous 
malformations are inherited vascular anomalies formed by abnormal vascular smooth muscle 
cells, called “glomus cells” caused by genetic alterations in glomulin (GLMN/FAP68) [66]. 
These mutations lead to up-regulation of the p70-S6 kinase activity, leading to the hypothesis 
that glomulin may play a part in the mTOR pathway [67]. 
 
Clinical implications and therapeutic opportunities 
 
Over the last decade, the development of targeted therapies has gained pace, mainly in the 
cancer field, largely as a consequence of the increased genetic and molecular understanding 
of the pathologies involved in malignancy. Such molecular pathophysiology has been lacking 
in vascular anomalies, explaining the relative lack of exploitation of targeted therapies. 
Vascular tumours are currently usually treated by chemotherapy, however, there are now 
growing pharmacologic options based on the use of anti-angiogenic drugs used for cancer 
therapy, including VEGFR inhibitors [68]. Vascular malformations are usually treated by 
surgical excision, pulsed laser therapy and sclerotherapy [69], but these treatments have 
limited efficacy and risk of recurrence.  
Empiric observations have also led to the use of specific drugs in some types of vascular 
tumours and malformations for which the underlying molecular mechanism of their 
therapeutic effect is unclear. An example is propranolol, a non-selective β-adrenergic blocker 
that is now the gold standard therapy for infantile haemangiomas [70]. To the best of our 
knowledge, propranolol has not been reported to have a therapeutic impact in other human 
vascular anomalies and showed no benefit in a pre-clinical mouse model of mutant Pik3ca-
induced VMs [38]. 
Progress in the sensitivity and speed of DNA sequencing techniques has identified 
causative genetic alterations of many diseases, even when present at low allelic frequencies, 
as in the case of some vascular anomalies in which mutant endothelial cells comprise a small 
proportion of the total lesional cell mass. This approach can provide specific diagnoses that 
ultimately will lead to personalised therapies. Since many of the genetic alterations in 
vascular anomalies are also described in a range of malignancies, drugs that are already used 
in the clinic or in clinical trials could be repurposed for these diseases. 
Specifically, the PI3K signalling pathway is a major drug target in cancer therapy, with 
many ongoing trials using pan- or isoform-selective PI3K inhibitors or dual PI3K/mTOR 
inhibitors [31,71]. In addition, the mTOR inhibitor rapamycin and its analogues are already 
approved for clinical use. These drugs were first used as immunosuppressive agents to 
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prevent transplant rejection, and are now employed for other indications including cancer, 
based on their anti-proliferative and anti-angiogenic effects [72]. 
Pre-clinical studies have shown that treatment of mice harbouring Pik3ca-mutant VMs 
with BYL719, a p110α-selective inhibitor currently in phase III trials, leads to a striking 
decrease in the volume of the VMs by diminishing endothelial cell proliferation [38]. 
Rapamycin and its analogue everolimus are also effective in the treatment of Pik3ca-mutant 
VMs in mice [37,38]. Rapamycin significantly reduces endothelial cell proliferation and 
blocks the loss of mural cell coverage of the vasculature in Pik3ca-mutant postnatal retinas 
[37]. Pre-clinical studies in mice have reported that rapamycin also efficiently blocks TEK-
mutant-driven VM growth, whereas a TIE2 tyrosine kinase inhibitor was not able to prevent 
lesional growth, probably because the compound used appears not to inhibit the mutant form 
of TIE2 [40]. Importantly, in a pilot study, rapamycin treatment of human patients with either 
TEK- or PIK3CA-mutant VMs led to significant clinical improvement [39,40]. Rapamycin 
and its analogues have also been demonstrated to be clinically effective in vascular anomalies 
in which the genetic cause has not been identified [73].  
Side effects of systemic administration of rapamycin mainly result from its immunological 
impact, including mucositis, stomatitis, oral ulcers and infections, with others including 
headaches, hypertension, insulin resistance and anaemia [74]. PI3K inhibitors have also been 
reported to be associated with various toxicities in patients upon systemic administration 
[75]; drug dose reduction of PI3K/mTOR inhibitors in this clinical setting may reduce such 
side effects while maintaining efficacy. In addition, topical administration in creams could 
also be a suitable alternative for the treatment of vascular anomalies since many of these 
lesions are present in the skin or subcutaneous tissue. In line with this, topical administration 
of rapamycin-based cream has been reported to offer clinical benefit in cutaneous vascular 
anomalies [62,76-78]. Similar strategies might be applied for PI3K inhibitors, as supported 
by preclinical evidence using topically applied PI3K inhibitors in Pik3ca-driven VMs in mice 
[38]. 
Unfortunately, lesions appear to recur upon cessation of rapamycin treatment, suggesting 
the need for continued drug administration in this disease. Indeed, following cessation of 
rapamycin treatment, symptoms recurred in human patients with TEK or PIK3CA-mutant 
VMs [39,40].  It is expected that targeting early components in the PI3K signalling pathway 
such as the PI3K isoforms themselves, rather than inhibiting downstream elements such as 
mTOR, might be more effective at pathway inhibition and result in a greater therapeutic 
impact. However, it remains to be determined whether PI3K inhibitors will provide effective 
lesional shrinkage with short-term treatment or also require continuous administration like 
rapamycin.  
 
In summary, there is growing evidence for PI3K pathway activation in the generation and 
maintenance of vascular anomalies. Developments and improvements in highly sensitive 
techniques for the detection of specific genetic alterations have led to enormous advances in 
identification and understanding of new mutations present in vascular anomalies, since they 
are often present at low allelic frequencies. It is anticipated that such analyses of vascular 
anomalies will lead to new genetic discoveries that will inform and direct future classification 
systems, allowing both more precise diagnoses and also, more importantly, development of 
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targeted therapies. PI3K pathway inhibitors are potentially promising as specific 
“personalised” therapies for certain vascular anomalies based on promising early results from 
pre-clinical and clinical studies. However, systemic administration of these drugs may be 
associated with toxicities, thus topical administration presents a likely sensible alternative for 
therapy of cutaneous vascular anomalies. 
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Figure 1. Photomicrographs demonstrating: (A) Combined type vascular malformation 
with venous components composed of dysplastic and dilated veins (two selected marked ‘V’; 
H&E, original magnification x10). (B) Lymphatic malformation composed of thin-walled 
dilated lymphatic channels containing lymph (two selected marked ‘L’; H&E, original 
magnification x20). (C) Infantile type capillary haemangioma composed of numerous 
capillary sized, thin-walled vessels (two selected marked with arrows; H&E, original 
magnification x40). (D) Infantile type capillary haemangioma with GLUT1 immunostaining 
showing lesional endothelial positivity (two selected marked with arrows; original 
magnification x40). 
 
Figure 2: Currently reported alterations in PI3K pathway components in vascular 
anomalies, and possible points of pharmacological interference. TIE2 and VEGFR2 also 
activate the MAPK pathway, which is not shown. PROS, PIK3CA-related overgrowth 
syndromes. 
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Current classification of vascular anomalies (simplified from www.issva.org). Asterisks 
indicate vascular anomalies in which mutational activation of the PI3K pathway has been 
reported.  
Vascular tumours Vascular malformations 
Benign 




Simple Combined Of major named 
vessels 
Associated with 
other anomalies 
 Capillary 
malformations 
 Lymphatic 
malformations 
 Venous 
malformations* 
 Arteriovenous 
malformations 
 Capillary-venous 
malformation 
 Capillary-
lymphatic 
malformation 
 Lympho-venous 
malformation 
 Other 
combination 
 Lymphatics 
 Veins 
 Arteries 
 Klippel-
Trenaunay 
syndrome* 
 Sturge-Weber 
syndrome 
 Proteus 
syndrome* 
Borderline 
 Kaposiform 
hemangioendothelioma 
 
Malignant 
 Angiosarcoma 
 
 
